Overview

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

In this trial investigators propose to assess the dose dense, G-CSF supported sequential administration of 4 cycles of FEC followed by 4 cycles of docetaxel versus 6 cycles of docetaxel/cyclophosphamide as adjuvant chemotherapy in women with HER-2 negative, axillary lymph node positive breast cancer

Phase:

Phase 3

Details

Lead Sponsor:

Hellenic Oncology Research Group

Collaborator:

University Hospital of Crete

Treatments:

Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Mitogens